icon
icon
icon
icon
Upgrade
upgrade

AngioDynamics (ANGO) 3 Oct 24 2025 Q1 Earnings call transcript

AInvestThursday, Oct 3, 2024 8:10 pm ET
1min read

AngioDynamics, a leading provider of minimally invasive, image-guided medical devices, reported a solid fiscal 2025 first quarter performance, showcasing the company's resilience and strategic focus on driving growth across its Med Tech and Med Device segments. The company's management team provided a comprehensive overview of the quarter's financial results, highlighting key growth initiatives and strategic moves that position AngioDynamics for long-term success.

Strong Financial Performance and Strategic Focus

AngioDynamics reported total worldwide revenue of $67.5 million for the fiscal 2025 first quarter, marking a 1% year-over-year growth. The company's Med Tech segment, driven by strong performance in Auryon and AlphaVac, recorded a 9% growth, demonstrating the success of its strategic product portfolio expansion. The company's adjusted EBITDA loss for the quarter was just $200,000, a significant improvement from the previous year, underscoring the company's progress towards profitability.

Key Growth Initiatives and Market Expansion

AngioDynamics' strategic focus on product innovation and market expansion was evident in its updates on key products and initiatives. The company's Auryon platform, which has shown outstanding results, is poised for further growth with the launch of Auryon XL and a 1.7 millimeter catheter. The CE mark approval for Auryon in Europe opens up a new market for the product, with the company planning a limited market release before a full market launch later in the year.

In the mechanical thrombectomy segment, AlphaVac continues to gain traction, with revenue increasing by over 21% despite the tough year-over-year comparison due to the impact of PERT, APEX trial participation, and the FDA clearance in early April. The product's strong performance is a testament to AngioDynamics' ability to meet the evolving needs of the clinical community and capitalize on market trends.

Manufacturing Transition and Financial Outlook

AngioDynamics' strategic shift towards outsourced manufacturing is on track, with the transition expected to generate approximately $15 million in annualized savings by fiscal 2027. The company's financial outlook for the fiscal year 2025 remains positive, with revenue growth projected in the range of 4.2% to 6.4% and adjusted EBITDA loss expected to be in the range of $2.5 million to zero.

Looking Ahead

AngioDynamics' strong first quarter performance and strategic initiatives provide a solid foundation for future growth. The company's focus on expanding its product portfolio, entering new markets, and optimizing its manufacturing operations demonstrate its commitment to driving long-term value for shareholders. As the company moves into the second quarter, investors and analysts will be watching closely to see how these strategic initiatives unfold and contribute to AngioDynamics' overall growth trajectory.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.